Abstract
The evaluation of combination chemotherapy regimens that incorporate new drugs has been accepted as the next rationale step in the development of new cytotoxic agents following the completion of phase I and early phase II trials. Before incorporating new agents into combination chemotherapy regimens, the new agent should have demonstrated a sufficient level of antitumor activity in relevant tumor types. In addition, adequate preclinical and clinical information about optimal scheduling should be available. New cytotoxic agents are often combined with platinum compounds, such as cisplatin and carboplatin, if the new agents possess relevant antitumor activity in ovarian, non-small and small cell lung, bladder, and germ cell carcinomas, as well as in other malignancies in which the platinum compounds are the mainstay of therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
E. Cadman, R. Heimer, L. Davis. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 205:1135 (1979).
C. Benz, E. Cadman E. Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Res. 41:994 (1981).
C. Benz, T. Tillis, E. Tattelman, E. Cadman. Optimal scheduling of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 42:2081 (1982).
N.E. Kemeny, T. Ahmed, R.A. Michaelson, H.D. Harper, L.C. Yip. Activity of sequential low dose methotrexate and 5-fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate. J Clin Oncol 2:311 (1984).
C. Benz, M. DeGregorio, S. Saks, et al. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response. Cancer Res 45:3354(1985).
J.L. Grem, C.J. Allegra. Sequence-dependent interactions of 5-fluorouracil and arabinosyl-5-azacytidine or 1-β-D-arabinfuranosylcytosine. Biochem Pharmacol 42:409 (1991).
R.A. Bender, W.A. Bleyer, S.A Frisby. Alteration of methotrexate uptake in human leukemia cells by other agents. Cancer Res. 35:1305 (1975).
R.F. Zager, S.A. Frisby, V.T. Oliverio. The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Res. 33:1670 (1993).
R.D. Warren, A.P. Nichols, R.A. Bender. The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells. Cancer Res. 37: 2993 (1977).
R.A. Bender, A.P. Nichols, L. Norton, et al. Lack of therapeutic synergism of vincristine and methotrexate in L1210 murine leukemia in vivo. Cancer Treat. Rep. 62:997 (1978).
E.K. Rowinsky, R.C. Donehower, R. J. Jones, R.W. Tucker. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 48:4093 (1988).
P. O’Connor, D. Ferris, G. White, et al. Relationship between cdc2 kinase activation, p34cdc2 dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res 52:1817 (1992).
J. Chou, P. Talalay. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs and enzyme inhibitors. Adv Enzyme Regul 22:27 (1984).
A.H. Calvert, D.R. Newell, L.A. Gumbrell. et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal functions. J Clin Oncol 7:1748 (1989).
D.I. Jodrell, M.J. Egorin, RM. Canetta, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520, (1992).
E.K. Rowinsky, M. Gilbert, W.P. McGuire, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692 (1991).
E.K. Rowinsky, M. Citardi, D.A. Noe, R.C. Donehower: Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine. J Can Res Clin Oncol 119:737 (1993).
R.J. Parker, M.D. Dabholkar, K-B Lee, F. Bostoick-Burton, E. Reed. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Monograph Natl Can. Inst. 15:83, (1993).
E. Reed, RJ. Parker, M. Dabholkar, et al. Taxol effect on cisplatin-DNA adduct repair in human ovarian cancer cells. (Abstract) Second National Cancer Institute Workshop on Taxol and Taxus. Alexandria, VA (1992).
G.A. LeBlanc, S.S. Sundseth, G.F. Weber, et al. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 5:540, (1992).
L.J.C. van Warmerdam, M.T. Huizing, S. Rodenhuis, et al: Can the Calvert formula predict the pharmacokinetics of carboplatin (C) when C is given in combination with paclitaxel (P). (Abstract) 7th International Symposium on Platinum and other metal coordination compounds in Cancer Chemotherapy. Abstract Book S67, Amsterdam, The Netherlands (March 1–4, 1995).
W.P. McGuire, W.J. Hoskins, M.R. Brady, et al. A phase III trial comparing cisplatin/cytoxan (pc) and cisplatin/taxol (pc) in advanced ovarian cancer (aoc). (Abstract) Proc Am Soc Clin Oncol 12:255 (1993).
F.A. Holmes, D. Frye, V. Valero. et al. Phase I study of taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer. (Abstract) Proc Am Soc Clin Oncol 11:600 (1992).
F.A. Holmes. Combination chemotherapy with Taxol (paclitaxel) in metastatic breast cancer. Ann Oncol 5(Suppl 6):S23–S27, 1994.
G.W. Sledge, N. Robert, J. Sparano, et al. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer. The Eastern Cooperative Oncology Group Experience. Sem Oncol 21(Suppl. 8):15 (1994).
M.J Kennedy, D. Armstrong, R. Donehower, et al. The hematologic toxicity of the taxol/cytoxan doublet is sequence-dependent. (Abstract) Proc Am Soc Clin Oncol 13:137, (1994).
E.K. Rowinsky (unpublished results).
L. Gianni, G. Straneo, F. Capri. et al: Optimal dose and sequence finding study of paclitaxel (P) by 3 h infusion with bolus doxorubicin (D) in untreated metastatic breast cancer patients (Pts). (Abstract) Proc Am Soc Clin Oncol 13:74 (1994).
J. Verweij, A.S.T. Planting, M.E.L. Van der Berg, et al: A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors. (Abstract) Proc Am Soc Clin Oncol 13:148, (1994).
E.J. Katz, J.S. Vick, K.M. Kling. et al. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. EurJ Cancer 26:724 (1990).
B. Drewinko, C. Green, T.L. Loo. Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II). Cancer Treat Rep 60:1619, (1976).
Y. Kano, K. Suzuki, M. Akutsu. et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604 (1992).
R. Johnson, F. McCabe, Y. Yu. Combination regimens with topotecan in animal tumor models. (Abstract) Ann Oncol 3(suppl 1):85, (1992).
K. Itoh, M. Takada, S. Kudo, et al. Synergistic effects of CPT-11 and cisplatin or etoposideon human lung cancer cell lines demonstrated by continuous infusion. (Abstract) Proc Am Assoc Cancer Res 33:259, (1992).
B. Drewinko, T.L. Loo, and E.J. Freireich. Combination chemotherapy in vitro. III. BCNU. Cancer Treat Rep 63:373 (1979).
M. Oguro. A topoisomerase I inhibitor, CPT-11: Its enigmatic antitumor activity in combination with other agents in vitro. (Abstract) In: Proceedings of the Third Conference on Topoisomerases, p 35 (1990).
E. Rowinsky, L. Grochow, S. Kaufmann, et al. Sequence-dependent effects of topotecan and cisplatin in a phase I and pharmacokinetic study. (Abstract) Proc Am Soc Clin Oncol 13:142, (1994).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rowinsky, E.K. (1996). Incorporating Assessments of Sequence-Dependence in Developmental Studies of Combination Chemotherapy Regimens Containing New Agents and Platinum Compounds. In: Pinedo, H.M., Schornagel, J.H. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0218-4_20
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0218-4_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0220-7
Online ISBN: 978-1-4899-0218-4
eBook Packages: Springer Book Archive